Regeneron Pharmaceuticals, Inc.

Other

University of California

St. Jude Children's Research Hospital

Neil E Stahl

George D Yancopoulos

Christos Kyratsous

Andrew J Murphy

William C Olson

Gang Chen

Aris N Economides

James P Fandl

Peter W Mason

Tammy T Huang

Robert Babb

Alina Baum

Wen-Yi Lee

Marine Malbec

Johanna Hansen

Cindy Gerson

Jamie M Orengo

Neil John Graham

Namita A Gandhi

David M Valenzuela

Nicholas J Papadopoulos

Margaret Karow

Eric Steven Furfine

Stanley J Wiegand

Jesse M Cedarbaum

Richard M Harland

Sumathi Sivapalasingam

Eduardo A Rojas

Lynn Macdonald

Samuel H Davis

Joel H Martin

Allen Radin

Jee Hwan Kim

Ashique Rafique

Chia-Yang Lin

Lori C Morton

Vivien Wong

Nicole M Alessandri-Haber

Scott Mellis

Nancy Y Ip

Jocelyn Holash

Nicholas W Gale

James N Ihle

Michael E Dunn

Steven P Weinstein

John Rudge

Brinda Prasad

Vishal Kamat

Joanne Papadopoulos

Peter S DiStefano

Denise Calaprice

Ellen M Koehler-Stec

Laura R Carpenter

Ishita Chatterjee

Wen-yi Lee

According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the target antigen with an ECof about 10 nM or less, and/or are capable of promoting complement deposition on the target antigen with an ECof about 10 nM. In certain embodiments, the bispecific antigen-binding molecules of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of an infectious agent or cancer cell is desired and/or therapeutically beneficial.

Compositions and methods for using bispecific antibodies to bind complement and a target antigen

The present disclosure provides novel immunoglobulin proteins that bind to a human natriuretic peptide receptor 1 (NPR1) agonist, preferably an anti-NPR1 antibody. In certain embodiments, the proteins of the disclosure comprise at least one immunoglobulin variable domain that binds to an anti-NPR1 antibody. In certain embodiments, the proteins of the disclosure are useful in blocking and/or reversing the effect of an administered anti-NPR1 antibody. In certain embodiments, the antigen-binding proteins are useful for effective management of blood pressure and hemodynamics in humans.

Immunoglobulin proteins that bind to NPR1 agonists

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

Human antibodies to ebola virus glycoprotein

Vascular endothelial growth factor (VEGF) traps and VEGF mini-traps that include VEGF receptor Ig-like domains, fused to a multimerizing component, are disclosed. The VEGF traps and VEGF mini-traps bind to VEGF and block its interaction with the VEGF receptor. Such molecules are useful for treating angiogenic eye disorders (e.g., age-related macular degeneration), cancer and for other undesired angiogenesis.

VEGF traps and mini-traps and methods for treating ocular disorders and cancer

Human antibodies to Ebola virus glycoprotein

The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R&#x3b1;) antagonist such as an anti-IL-4R&#x3b1; antibody.

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor

Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptor

A method of detecting and isolating cells that produce a secreted protein of interest (POI), for example, an antibody, comprising: a) providing a eukaryotic cell comprising (i) a nucleic acid encoding the POI, and (ii) a nucleic acid encoding a cell surface capture molecule, which comprises a membrane anchor and is capable of binding the POI; (b) culturing the cell under conditions in which the POI and cell surface capture molecule are expressed, and a POI-cell surface capture molecule complex is formed intracellularly and displayed on the cell surface; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule.

Isolating cells expressing secreted proteins

Growing community of inventors

Carmel, NY, United States of America

Neil E Stahl